-+ 0.00%
-+ 0.00%
-+ 0.00%
Did No Cost Exome Testing Just Shift GeneDx Stock's Investment Narrative?
Share
Listen to the news
  • GeneDx Holdings reported third quarter 2026 revenue of US$123.1 million and a net loss of US$12.33 million, reaffirmed full year revenue guidance, and highlighted new research plus a collaboration with Mirum Pharmaceuticals to expand access to no cost exome testing in rare diseases.
  • The mix of deeper clinical utility data on exome and genome sequencing, Mirum funded testing programs, and wider guidance disclosure gives investors a clearer view of how GeneDx’s testing volumes, reimbursement prospects, and operating scale may interact over time.
  • Attention now turns to how GeneDx Holdings’ expanded no cost exome testing with Mirum reshapes the longer term investment narrative around rare disease genomics.

Scan for other rare disease genomics stories with similar momentum by reviewing the curated 36 healthcare AI stocks alongside GeneDx Holdings after this update.

GeneDx Holdings Investment Narrative Recap

To stay invested in GeneDx Holdings, investors need to believe the rare disease testing engine can convert payer coverage and volume growth into healthier unit economics. The analyst consensus Narrative on Simply Wall St leans on that idea. The latest quarter delivered US$123.1 million in revenue, and management kept full year guidance, which supports that operating thesis even as the firm remains loss making.

The near term swing factor is still whether reimbursement collection and cost discipline can tighten the gap between revenue and cash generation. A net loss of US$12.33 million for the quarter and US$93.38 million for the nine months keeps financing and payer risk very real, so execution on collections and spending remains front of mind.

The Mirum Pharmaceuticals collaboration is the clearest operational tie in to those catalysts. Fully sponsored exome testing programs in cholestasis, early onset cataracts and PBD ZSD can feed more complex cases into GeneDx Holdings, deepen its database and support use of exome in frontline pediatrics without adding billing friction for eligible patients.

That matters because the business case hinges on higher test volumes, richer clinical data and better reimbursement all moving together. Sponsored programs reduce financial barriers for a subset of rare disease patients, create incremental ordering habits for clinicians and can support the broader push to improve outpatient collection rates if the company demonstrates its tests consistently inform diagnosis and management.

GeneDx Holdings' current earnings are a loss of US$106.4 million, and analysts expect earnings to reach US$29.2 million by 2029. This implies an earnings improvement of about US$135.6 million alongside forecast revenue of US$795.7 million and an assumed 20.5% yearly revenue growth rate.

Discover why GeneDx Holdings' fair value indicates a 79% potential upside to its current price, which could narrow quickly.

NasdaqGS:WGS 1-Year Stock Price Chart
NasdaqGS:WGS 1-Year Stock Price Chart

Exploring Other Perspectives

One bullish twist in the alternate GeneDx Holdings story is how aggressively some analysts leaned into the Mirum style reimbursement catalyst even before this collaboration. The most optimistic forecasts had revenue reaching about US$906.1 million by 2029 and earnings at roughly US$24.2 million. That is a much richer outlook than consensus, and it shows how far opinions can spread. Use this earnings release and the new exome programs as a prompt to compare those viewpoints and decide which assumptions feel realistic for your own analysis.

Explore 4 other GeneDx Holdings fair value estimates, including one that suggests as much as 353% upside from the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking for more GeneDx Holdings style investment ideas?

Once you have formed a view on GeneDx Holdings, it can help to cross check that thesis against other opportunities with different risk and return profiles using the Simply Wall St Screener.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending